Fisher Asset Management LLC Acquires 105,333 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Fisher Asset Management LLC boosted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 12.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 960,661 shares of the biopharmaceutical company's stock after buying an additional 105,333 shares during the quarter. Fisher Asset Management LLC owned approximately 1.68% of Agios Pharmaceuticals worth $31,567,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after acquiring an additional 216,484 shares during the period. Vestal Point Capital LP bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at $33,767,000. BNP Paribas Financial Markets grew its position in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after purchasing an additional 1,570 shares in the last quarter. FMR LLC increased its holdings in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock worth $2,017,000 after purchasing an additional 33,546 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the third quarter worth $892,000.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock traded up $0.08 during mid-day trading on Thursday, hitting $34.03. The company's stock had a trading volume of 154,029 shares, compared to its average volume of 749,225. The business has a 50 day moving average price of $33.83 and a 200-day moving average price of $42.54. Agios Pharmaceuticals, Inc. has a 12 month low of $27.14 and a 12 month high of $62.58. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of 3.00 and a beta of 0.88.

Remove Ads

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AGIO shares. Royal Bank of Canada boosted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 target price on the stock. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, December 9th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $56.57.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.